Journal of Clinical and Aesthetic Dermatology

Plaque-type Psoriasis Supplement 2016

An evidence-based, peer-reviewed journal for practicing clinicians in the field of dermatology

Issue link:

Contents of this Issue


Page 1 of 15

S2 SUPPLEMENT TO THE JOURNAL OF CLINICAL AND AESTHETIC DERMATOLOGY [JUNE 2016 • VOLUME 9 • NUMBER 6 • SUPPLEMENT 1] As clinicians, our view of psoriasis can become skewed by the cases we happen to see in our own practices. Although our journals continuously report on promising therapeutic pathways by which to target severe disease, the majority of our patients probably have mild-to-moderate disease that can be treated topically. Even in this so-called "Age of Biologics," we may find it difficult to keep track of the latest data, recommendations for pre-screening and monitoring and, of course, the various requirements for preauthorizations and insurance coverage. This is especially true if we serve a small population of patients with moderate-to-severe disease. But the reality is that, even if they represent just a small percentage of our patient population, there are patients struggling with moderate-to-severe psoriasis who need—and deserve—systemic treatments, including biologics. The novel class of interleukin-17 (IL-17) inhibitors shows extraordinary promise for the treatment of moderate-to-severe plaque psoriasis and represents an exciting new direction in patient care. The IL-17 pathway in psoriasis is one that researchers are still exploring. This cytokine is implicated in mediating inflammation, and excess signaling is clearly involved in psoriasis. The potential applications of IL-17 mediation likely include therapeutic targets beyond the skin. However, for us who treat skin disease, its application in psoriasis care presents new opportunities. Research to date shows that IL-17 mediators can provide rapid clearance of psoriasis; notable benefits are visible in a significant majority of patients within 12 weeks. Complete clearance or close to complete clearance rates at 12 weeks are especially impressive. As with all systemic therapies, safety is a concern with IL-17 agents. Although there seems to be no significant safety signals with IL-17 modulation from the clinical studies, we still have to be cognizant about possible adverse events at post- marketing as those agents are used in larger populations. Taken together, the data for IL-17 agents remind us that the "Age of Biologics" is still young, but full of promise. New therapeutic pathways may yet yield even more effective, safe options for patients with moderate-to-severe psoriasis. As dermatology providers, we have a responsibility to be aware of new developments and therapeutic options available to us, and be prepared to adopt and incorporate appropriate new agents into practices so that we can effectively treat our psoriasis patients. J Clin Aesthet Dermatol. 2016;9(6 Suppl):S1–S12 Leon Kircik, MD Associate Clinical Professor Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York Dr. Kircik has served either as an advisor, an investigator, a consultant, or a speaker for Novartis, Amgen, Idera, Biogen, Merck, Sandoz, Boehringer- Ingleheim, Eli Lilly, and Centocor. Dr. Kircik has received compensation from JCAD for his editorial support. Support provided by Novartis © 2016 Matrix Medical Communications • 1595 Paoli Pike • Suite 201 • West Chester, PA 19380; Toll-free: (866) 325-9907 • Phone: (484) 266-0702 New Age Of Biologics

Articles in this issue

Links on this page

Archives of this issue

view archives of Journal of Clinical and Aesthetic Dermatology - Plaque-type Psoriasis Supplement 2016